

Appendix 4C Quarterly Cash Flow and Market Update

Australian Dairy Nutritionals Group Limited (**AHF** or the **Group**) advises that this activity report relates to the Appendix 4C for the quarter ended 31 March 2023 (**Quarter**) released to the market on 28 April 2023.

Sales and Distribution

The Group remains focussed on building distribution of its products in international markets and growing domestic sales performance. A brief update follows in relation to each of the Group's brands:

(a) Ocean Road Dairies Organic A2 Protein Infant Formula Range

AHF received export certification of its Depot Road manufacturing facility in February 2023 and has commenced production of inventory of the Ocean Road Dairies infant formula range for export to international markets.

We have received an order from the Group's distributor for the Ocean Road Dairies JD.com flagship store and will be dispatched early May 2023.

(b) Future Gradulac Gentle Infant Formula Range

Sales of the future Gradulac Gentle range have been slower than anticipated. The Group has appointed a distributor for the range in Malaysia and is working through the registration process for this market. Inventory levels are being closely managed and no further investment in inventory is required at this stage to support existing distribution arrangements and ongoing opportunities.

We are in advanced discussions with distributors in other international markets for this range and are confident of successfully concluding negotiations with sales to follow.

Farms

Farm milk production and revenues were stronger than the comparative period last year due to intermittent rains during the summer period and relatively cooler summer temperatures. All farms are in excellent condition ready for the commencement of the autumn break and have already received good early rainfall.

As noted previously, the Group has leased part of an organic certified farm nearby the Brucknell farms to grow a portion of the farm's organic grain requirements. Seed was planted last week following good rainfall at the property over the past month and harvest is expected in November/December 2023.

Subject to seasonal conditions and yield assumptions, we estimate this will allow the Group to grow approximately 30% of its supplemental feed requirements at a materially lower cost than current market prices and, assists in securing organic grain supply for our dairy farms for next season.

Cash Position

The Board is closely monitoring the Group's cash position as it navigates this period of investment in export inventory and personnel in anticipation of future product sales. On 23 March 2023 the Group announced a private placement to raise \$1,000,000 through the issue of 33,333,333 new shares at \$0.03 and the placement completed on 26 April 2023.

The Board has a number of short, medium and long-term strategies for management of the Group's cash position to ensure operations are well funded. As noted above, current inventory holdings of the Group's infant formula products are sufficient to support ongoing development of our distribution network and discussions are advanced with several potential distribution partners.

The Group is also continuing to progress the sale of residual dairy processing equipment as part of the closure of the Manifold Street site. In addition, the Group has capital raising opportunities available to it from existing shareholders and sophisticated investors as well as debt funding arrangements.

Quarterly Activity Report (QAR) – Additional Information for the quarter ended 31 March 2023 (Quarter)

(a) Details of the Company's Business Activities for the Quarter

The Group's business activities during the Quarter focussed on dairy farming and dairy manufacturing. The Expenditure reported in the Quarter relates primarily to:

- dairy farm operating costs including feed and employment costs;
- infant formula production costs including purchase of raw materials, packaging, employment and other associated manufacturing costs; and
- corporate costs in relation to the Group including employment costs, ASX fees, registry fees, insurance and professional fees.

(b) Payments to an associate of, a related party of the Company (section 6 of Appendix 4C)

Section 6 of the Appendix 4C reports expenditure of \$120,000 paid to the Directors during the Quarter. This figure includes \$72,425 in Director fees and \$47,500 of consulting fees paid to Jason Dong for consulting services in relation to the China market. Shareholders should note that this figure no longer includes payments to Peter Skene as he is no longer considered a related party of the Company.

The release of this announcement was authorised by the Board of AHF.

Ends

Further Details

Australian Dairy Nutritionals Limited

Phone: +61 3 8692 7284

Email: shareholders@adnl.com.au

About Australian Dairy Nutritionals Group

Australian Dairy Nutritionals Group (AHF) is a vertically integrated Australian dairy group which owns high quality organic and organic A2 dairy farms, and a processing facility located in Southwestern Victoria, the 'Golden Triangle' of Australia's dairy industry. In addition to our premium Future range of infant formulas the Group has also commenced production of Australia's first Organic A2 infant formula made with farm fresh Australian milk from our farms at our purpose-built infant formula factory.

Disclaimer – Forward Looking Statements

This announcement may include "forward looking statements" within the meaning of securities laws of applicable jurisdictions. These forward-looking statements are not historical facts but are based on AHF's current expectation, estimates and projections about the industry, in which it operates, and beliefs and assumptions. Readers are cautioned not to place undue reliance on forward looking statements.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Australian Dairy Nutritionals Group: Comprising
Australian Dairy Nutritionals Limited – ABN: 36 057 046 607; and
Australian Dairy Farms Trust – ARSN: 600 601 689

ABN

See Above

Quarter ended (“current quarter”)

31 March 2023

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	2,063	7,366
1.2 Payments for		
(a) research and development	-	-
(b) product manufacturing and operating costs	(2,344)	(8,677)
(c) advertising and marketing	(158)	(435)
(d) leased assets	-	-
(e) staff costs	(587)	(2,013)
(f) administration and corporate costs	(501)	(1,616)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	1	2
1.5 Interest and other costs of finance paid	(29)	(70)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(1,555)	(5,443)
2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(128)	(793)
(d) investments	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
	(e) intellectual property	-	-
	(f) other non-current assets	(18)	(81)
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	6,094
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other	-	-
2.6	Net cash from / (used in) investing activities	(146)	5,220

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	631
3.6	Repayment of borrowings	(184)	(927)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other – lease liabilities	(113)	(338)
3.10	Net cash from / (used in) financing activities	(297)	(634)

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	3,573	2,432
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,555)	(5,443)

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(146)	5,220
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(297)	(634)
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of period	1,575	1,575

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	1,575	3,573
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	1,575	3,573

6. Payments to related parties of the entity and their associates

- 6.1 Aggregate amount of payments to related parties and their associates included in item 1.
- 6.2 Aggregate amount of payments to related parties and their associates included in item 2

**Current quarter
\$A'000**

120

-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

6.1 The \$120,000 comprises fees paid to the Directors during the Quarter. This figure includes \$72,425 in Director fees and \$47,500 of consulting fees paid to Jason Dong for consulting services in relation to the China market. Shareholders should note that this figure no longer includes payments to Peter Skene as he is no longer considered a related party of the Company.

7. Financing facilities

Note: the term "facility" includes all forms of financing arrangements available to the entity.

Add notes as necessary for an understanding of the sources of finance available to the entity.

	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (Short-term credit facility - insurance)	203	203
7.4 Total financing facilities	203	203

7.5 **Unused financing facilities available at quarter end** nil

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

7.3 Premium Funding (Insurance) – Unsecured short-term loan facility. Flat interest rate: 4.10%.

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (Item 1.9)	(1,555)
8.2 Cash and cash equivalents at quarter end (Item 4.6)	1,575
8.3 Unused finance facilities available at quarter end (Item 7.5)	-
8.4 Total available funding (Item 8.2 + Item 8.3)	1,575
8.5 Estimated quarters of funding available (Item 8.4 divided by Item 8.1)	1.01

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:

The current level of net operating cash flows is expected to continue in the short-term. The Group expects to increase cash flows as it commercialises the sale of its infant formula ranges in overseas markets.

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

As announced to the ASX on 23 March 2023, the Group raised \$1,000,000 through a private placement of 33,333,333 new shares at \$0.03 per share. The placement proceeds are not reflected in this Appendix 4C as the placement completed on 26 April 2023. In addition, the Group has capital raising opportunities available to it from existing shareholders and sophisticated investors as well as debt funding arrangements.

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

Yes. The Board is closely monitoring the cash position of the Group and has a number of short, medium and long-term strategies for management of the Group's cash position to ensure operations are well funded. Current inventory holdings of the Group's infant formula products are sufficient to support ongoing development of our distribution network and discussions are advanced with several potential distributors. Furthermore, the Group is continuing to progress the sale of residual dairy processing equipment as part of the closure of the Manifold Street site. In addition, the Group has capital raising opportunities as outlined in section 8.6.2 (above).

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 28 April 2023

Authorised by: the Board of Directors

(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.